rs12693542 — SLC40A1

Regulatory variant upstream of ferroportin (the sole cellular iron exporter) linked to restless legs syndrome through impaired brain iron delivery

See your personal result for SLC40A1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SLC40A1 — The Brain's Iron Export Gate and Restless Legs Syndrome

Every neuron, including the dopamine-producing cells of the substantia nigra11 substantia nigra
The midbrain region housing dopaminergic neurons whose iron stores are consistently reduced in restless legs syndrome even when blood iron is normal, depends on a steady supply of iron to sustain normal function. But iron cannot simply diffuse into the brain — it must cross specialized barriers, and the protein that controls its export from cells along this route is ferroportin22 ferroportin
The sole known mammalian iron exporter, encoded by SLC40A1 on chromosome 2, expressed on enterocytes, macrophages, and critically the choroid plexus epithelial cells and ependymal cells lining the brain's ventricles. The rs12693542 variant sits approximately two kilobases upstream of the SLC40A1 gene in a regulatory region, where it influences how much ferroportin the cell produces. The G allele — a minority variant in most populations — is associated with increased susceptibility to restless legs syndrome33 restless legs syndrome
Also called Willis-Ekbom disease; a neurological condition causing irresistible urges to move the legs, typically at rest and worst in the evening, affecting 5-10% of adults.

The Mechanism

Restless legs syndrome is not, as was long assumed, primarily a dopamine disorder. Post-mortem neuropathology44 Post-mortem neuropathology
Connor JR et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology, 2003 consistently shows iron-deficient substantia nigra in RLS brains, but the cellular machinery looks normal: no dopaminergic degeneration, no Lewy bodies. The iron simply isn't getting in. The iron stores of [neuromelanin cells | Pigmented dopamine-producing neurons in the substantia nigra that normally accumulate large iron deposits through the lifespan] — which normally accumulate iron throughout life — are markedly depleted in RLS brains compared to age-matched controls.

The route iron takes into the brain is circuitous. Iron from the bloodstream enters [choroid plexus | A network of epithelial cells in the brain's ventricles that produces cerebrospinal fluid and acts as a selective iron gateway into the CNS] epithelial cells, crosses those cells, and is then exported via ferroportin into cerebrospinal fluid, which delivers iron to brain tissue. A second route crosses the blood-brain barrier microvasculature. Studies of RLS brains55 Studies of RLS brains
Connor JR et al. Profile of altered brain iron acquisition in restless legs syndrome. Brain, 2011 found paradoxically elevated ferroportin in the choroid plexus of RLS patients — a likely compensatory response to the iron-deficient brain environment — alongside reduced IRP1 activity, suggesting dysregulated cellular iron sensing.

Critically, laser capture microdissection66 laser capture microdissection
Connor JR et al. Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. Neurology, 2004 of individual neuromelanin cells from RLS substantia nigra found reduced ferroportin, reduced transferrin receptor, reduced H-ferritin, and reduced IRP1 protein — a signature of cellular iron starvation despite the compensatory upregulation at the choroid plexus. The upstream variant rs12693542 presumably modulates the baseline expression of SLC40A1, shifting the equilibrium of this already-fragile brain iron delivery system.

Hepcidin-ferroportin signaling77 Hepcidin-ferroportin signaling
Clardy SL et al. Is ferroportin-hepcidin signaling altered in restless legs syndrome? J Neurol Sci, 2006 is also disrupted in RLS — pro-hepcidin was significantly decreased in CSF of early-onset RLS patients, while brain tissue showed elevated pro-hepcidin in the substantia nigra and putamen. This bidirectional hepcidin dysregulation compounds any genetically reduced ferroportin expression, creating a milieu in which the brain chronically under-delivers iron to precisely the neurons that need it.

The Evidence

The Schormair et al. 2024 meta-analysis88 Schormair et al. 2024 meta-analysis
Schormair B et al. Genome-wide meta-analyses of restless legs syndrome yield insights into genetic architecture, disease biology and risk prediction. Nature Genetics, 2024 represents the definitive population genetics study of RLS to date — 116,647 cases and 1,546,466 controls of European ancestry, increasing the total genome-wide significant loci from 20 to 164. rs12693542 in the SLC40A1 regulatory region reached p=1.35×10⁻¹³, comfortably beyond genome-wide significance (p<5×10⁻⁸). This places it among the most robustly replicated common genetic risk factors for RLS, and directly implicates the ferroportin expression axis in disease pathogenesis.

The biological plausibility is high. Multiple independent lines of evidence converge: the neuropathological iron deficiency in RLS substantia nigra, the aberrant ferroportin expression at the blood-brain interface, the disrupted hepcidin-ferroportin signaling in RLS CSF and brain tissue, and now the GWAS signal upstream of the gene encoding ferroportin itself.

Practical Actions

The clinical implications follow directly from the pathophysiology. Iron therapy is an established first-line treatment for RLS when serum ferritin is low, and even in patients with "normal" peripheral iron. Current guidelines recommend iron supplementation when ferritin is below 75 µg/L, as clinical trials reviewed by Trenkwalder et al.99 clinical trials reviewed by Trenkwalder et al.
Trenkwalder C et al. Comorbidities, treatment, and pathophysiology in restless legs syndrome. Lancet Neurology, 2018 demonstrate that intravenous iron preparations (ferric carboxymaltose, ferric gluconate) significantly reduce RLS symptom severity. The therapeutic target for brain iron delivery is a serum ferritin well above the lower limit of the normal reference range — typically 100-150 µg/L for optimal neurological iron availability.

Oral iron supplementation is also effective for milder cases. Iron bisglycinate is better tolerated and has higher bioavailability than ferrous sulfate. Ferritin should be monitored at 3-month intervals when supplementing to track response and avoid overcorrection.

Importantly, the brain iron deficit in RLS is not simply a mirror of peripheral iron status. Some RLS patients have normal serum ferritin yet still respond to iron therapy, suggesting that the genetic variants affecting iron transport at the blood-brain interface — including SLC40A1 regulatory variants — create a CNS-specific iron insufficiency that is only partially captured by serum ferritin.

Interactions

rs12693542 operates within the broader iron homeostasis network. Three key interaction partners are represented elsewhere in the GeneOps database:

HFE variants rs1800562 (C282Y) and rs1799945 (H63D) cause hereditary hemochromatosis by raising serum iron — paradoxically, some hemochromatosis patients can still have RLS if brain iron delivery is impaired despite elevated peripheral iron. The combination of HFE iron overload genotype with the SLC40A1 upstream risk allele (reduced ferroportin expression) creates opposing pressures on the systemic versus neurological iron axis.

TMPRSS6 rs855791 (Ala736Val) affects hepcidin suppression and iron absorption efficiency. Individuals carrying both the TMPRSS6 A allele (reduced iron absorption) and the SLC40A1 G allele (impaired brain iron delivery) face compounded disadvantage: less iron in the bloodstream to begin with, and less efficient delivery to the CNS. This compound exposure likely represents the highest-risk subgroup for RLS driven by iron insufficiency.

Nutrient Interactions

iron increased_need

Genotype Interpretations

What each possible genotype means for this variant.

AA Standard RLS Risk Normal

Common ferroportin expression pattern — population-typical RLS susceptibility

You carry two copies of the A allele at this regulatory site upstream of SLC40A1, the most common genotype globally (approximately 46% of people worldwide, and over 50% of Europeans). Your ferroportin expression follows the typical population pattern, and you carry no excess genetic risk for restless legs syndrome from this variant.

This does not mean zero RLS risk — the condition is influenced by many factors including iron status, sleep patterns, pregnancy, kidney disease, and medications. But rs12693542 itself does not contribute elevated risk.

AG Mildly Elevated Risk Intermediate

One copy of the RLS-associated regulatory variant — modest increase in susceptibility

As a heterozygous carrier, you have one copy of the risk G allele that can shift ferroportin expression in the regulatory regions of choroid plexus and ependymal cells — the cells that mediate iron transit into cerebrospinal fluid and then to brain tissue. The additive genetic architecture means your brain iron delivery capacity is intermediate: better than GG homozygotes but below the AA baseline.

The clinical significance becomes most apparent when peripheral iron is marginal. At ferritin levels of 50-75 µg/L (technically "normal" by most lab reference ranges), the brain may receive insufficient iron for optimal dopaminergic function, and the slightly reduced ferroportin expression your G allele likely confers makes you somewhat less tolerant of iron stores that are suboptimal but not technically deficient.

GG Elevated RLS Risk High Risk

Two copies of the RLS-associated regulatory variant — meaningfully elevated susceptibility

The GG genotype places you at the highest-risk end of the SLC40A1 distribution for RLS susceptibility. Post-mortem studies of RLS brains show a characteristic pattern: iron staining markedly reduced in the substantia nigra, H-ferritin minimal, transferrin elevated (a sign the cell is starving for iron and importing more transferrin-bound iron), and ferroportin and IRP1 protein reduced in neuromelanin cells. This neuropathological fingerprint suggests that impaired iron delivery — rather than dopaminergic neurodegeneration — underlies RLS.

Your GG genotype at rs12693542 likely reduces the baseline expression of ferroportin (SLC40A1) in the choroid plexus epithelial cells and ependymal cells that form the iron gate into cerebrospinal fluid. Even a modest reduction in ferroportin expression at this critical chokepoint can substantially reduce the iron flux into the brain's fluid compartments, starving dopaminergic neurons over time.

Importantly, brain iron deficiency in RLS is often invisible to standard blood tests — serum ferritin can be within the normal reference range while the brain is functionally iron-deficient. This means standard clinical thresholds may underdetect iron insufficiency in individuals with this genotype. The therapeutic target for neurological iron availability is ferritin well above the lower normal limit: current practice guidelines for RLS indicate iron therapy when ferritin is below 75 µg/L, with evidence supporting even higher targets (100-150 µg/L) for symptomatic patients.